
    
      In Part A of the study, participants after confirmation of the diagnosis of NPC will receive
      VTS-270 for 20 weeks during the active treatment period. Further, based on investigator's
      discretion participants would either end treatment with a follow-up visit 28 days (+/- 7)
      days after last treatment, or will enter to Part-B to benefit from open-label treatment.
    
  